DSGN.US Design Therapeutics Inc

Healthcare Biotechnology USA Stocks
10.47 USD
Close of Nov 14, 2026
7.24 17.25
Market cap
USD 670M
P/E
-
P/B
3.35x
ROE
-38.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is DSGN.US undervalued?

Graham number

The Graham number of Design Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Design Therapeutics Inc fundamental analysis

No fundamental analysis for Design Therapeutics Inc yet.

Design Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Design Therapeutics Inc

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autos…

Full company profile